Last reviewed 2026-04-22 · How we verify

NAFT500 (pediatric)

Merz North America, Inc. · FDA-approved active Small molecule

NAFT500 (pediatric) is a Allylamine antifungal Small molecule drug developed by Merz North America, Inc.. It is currently FDA-approved for Tinea pedis (athlete's foot) in pediatric patients, Tinea cruris (jock itch) in pediatric patients, Tinea corporis (ringworm) in pediatric patients. Also known as: NAFT500, naftifine, naftifine hydrochloride.

NAFT500 is a naftifine hydrochloride topical antifungal that inhibits fungal sterol synthesis by blocking squalene epoxidase.

NAFT500 is a naftifine hydrochloride topical antifungal that inhibits fungal sterol synthesis by blocking squalene epoxidase. Used for Tinea pedis (athlete's foot) in pediatric patients, Tinea cruris (jock itch) in pediatric patients, Tinea corporis (ringworm) in pediatric patients.

At a glance

Generic name	NAFT500 (pediatric)
Also known as	NAFT500, naftifine, naftifine hydrochloride
Sponsor	Merz North America, Inc.
Drug class	Allylamine antifungal
Target	Squalene epoxidase
Modality	Small molecule
Therapeutic area	Dermatology / Infectious Disease
Phase	FDA-approved

Mechanism of action

Naftifine is an allylamine-class antifungal that disrupts ergosterol biosynthesis in fungal cell membranes by inhibiting the enzyme squalene epoxidase. This leads to accumulation of squalene and depletion of ergosterol, destabilizing the fungal cell membrane and causing fungal cell death. The pediatric formulation (NAFT500) is designed for safe topical use in children.

Approved indications

Tinea pedis (athlete's foot) in pediatric patients
Tinea cruris (jock itch) in pediatric patients
Tinea corporis (ringworm) in pediatric patients

Common side effects

Local skin irritation
Burning or stinging at application site
Erythema
Pruritus

Key clinical trials

Pharmacokinetic Study of Pediatric Subjects With Tinea Cruris and Tinea Pedis (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

NAFT500 (pediatric) CI brief — competitive landscape report
NAFT500 (pediatric) updates RSS · CI watch RSS
Merz North America, Inc. portfolio CI

Frequently asked questions about NAFT500 (pediatric)

What is NAFT500 (pediatric)?

NAFT500 (pediatric) is a Allylamine antifungal drug developed by Merz North America, Inc., indicated for Tinea pedis (athlete's foot) in pediatric patients, Tinea cruris (jock itch) in pediatric patients, Tinea corporis (ringworm) in pediatric patients.

How does NAFT500 (pediatric) work?

NAFT500 is a naftifine hydrochloride topical antifungal that inhibits fungal sterol synthesis by blocking squalene epoxidase.

What is NAFT500 (pediatric) used for?

NAFT500 (pediatric) is indicated for Tinea pedis (athlete's foot) in pediatric patients, Tinea cruris (jock itch) in pediatric patients, Tinea corporis (ringworm) in pediatric patients.

Who makes NAFT500 (pediatric)?

NAFT500 (pediatric) is developed and marketed by Merz North America, Inc. (see full Merz North America, Inc. pipeline at /company/merz-north-america-inc).

Is NAFT500 (pediatric) also known as anything else?

NAFT500 (pediatric) is also known as NAFT500, naftifine, naftifine hydrochloride.

What drug class is NAFT500 (pediatric) in?

NAFT500 (pediatric) belongs to the Allylamine antifungal class. See all Allylamine antifungal drugs at /class/allylamine-antifungal.

What development phase is NAFT500 (pediatric) in?

NAFT500 (pediatric) is FDA-approved (marketed).

What are the side effects of NAFT500 (pediatric)?

Common side effects of NAFT500 (pediatric) include Local skin irritation, Burning or stinging at application site, Erythema, Pruritus.

What does NAFT500 (pediatric) target?

NAFT500 (pediatric) targets Squalene epoxidase and is a Allylamine antifungal.

Drug class: All Allylamine antifungal drugs
Target: All drugs targeting Squalene epoxidase
Manufacturer: Merz North America, Inc. — full pipeline
Therapeutic area: All drugs in Dermatology / Infectious Disease
Indication: Drugs for Tinea pedis (athlete's foot) in pediatric patients
Indication: Drugs for Tinea cruris (jock itch) in pediatric patients
Indication: Drugs for Tinea corporis (ringworm) in pediatric patients
Also known as: NAFT500, naftifine, naftifine hydrochloride

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing